Rubric Capital Management LP Karyopharm Therapeutics Inc. Transaction History

Rubric Capital Management LP

9 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2023 Aug 11, 2023	SELL	$1.79 - $4.59 $6.3 Million - $16.2 Million	-3,521,860 Reduced 79.3%	919,196 $1.65 Million
Q1 2023 May 12, 2023	SELL	$2.84 - $3.92 $10.9 Million - $15.1 Million	-3,853,565 Reduced 46.46%	4,441,056 $17.3 Million
Q4 2022 Feb 10, 2023	BUY	$2.48 - $5.93 $10.7 Million - $25.5 Million	4,304,495 Added 107.88%	8,294,621 $28.2 Million
Q3 2022 Nov 14, 2022	SELL	$4.08 - $5.82 $1.67 Million - $2.39 Million	-409,874 Reduced 9.32%	3,990,126 $21.8 Million
Q2 2022 Aug 15, 2022	BUY	$4.15 - $8.37 $3.29 Million - $6.63 Million	792,557 Added 21.97%	4,400,000 $19.8 Million
Q1 2022 May 13, 2022	BUY	$5.91 - $14.38 $4.88 Million - $11.9 Million	825,000 Added 29.65%	3,607,443 $26.6 Million
Q4 2021 Feb 14, 2022	SELL	$5.21 - $8.61 $3.09 Million - $5.11 Million	-593,315 Reduced 17.58%	2,782,443 $17.9 Million
Q3 2021 Nov 12, 2021	SELL	$4.45 - $10.63 $3.9 Million - $9.33 Million	-877,454 Reduced 20.63%	3,375,758 $19.6 Million
Q2 2021 Aug 13, 2021	BUY	$8.11 - $11.11 $34.5 Million - $47.3 Million	4,253,212 New	4,253,212 $43.9 Million

57.6M

258K

81.2K

Ticker KPTI
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 79,806,600
Market Cap $52.7M
Description
Karyopharm Therapeutics Inc., a commercial-stage pharmaceutical company, discovers, develops, and commercializes drugs directed against nuclear export for the treatment of cancer and other diseases. The company discovers, develops, and commercializes novel and Selective Inhibitor of Nuclear Export (SINE) compounds function by binding with and in...

Get notified when there are updates to the investment portfolio of Rubric Capital Management LP, based on Form 13F filings with the SEC.

Stay updated on Rubric Capital Management LP with notifications on news.